Skip to main content
72°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Relief Therapeutics Holdings AG
< Previous
1
2
3
Next >
Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19
November 03, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Positive Interim Data from Its Clinical Trial of Novel Nasal Spray Sentinox in SARS-CoV-2 Infected Patients
October 27, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Therapeutics Reports Two Publications of Positive Data on Nexodyn(R) AOS for Hard-to-Heal Ulcers
October 20, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure
October 15, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
October 13, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Therapeutics Announces Filing of Lawsuit Against its U.S. Collaboration Partner, NeuroRx, Inc. and its CEO, Dr. Jonathan Javitt, for RLF-100(TM) (Aviptadil)
October 06, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
COVID-19
Financial
Legal
Tickers
RLFTF
Relief Reports that U.S. Collaboration Partner Announced Second Favorable Safety Report for ZYESAMI(TM) (RLF-100TM/aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Life-Threatening COVID-19
September 30, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief's Subsidiary, APR Applied Pharma Research, Reports Data Published in Journal of Wound Care, Indicating Nexodyn(R) AOS Highly Effective Treatment to Support Healing of Hard-to-Heal Leg Ulcers
September 30, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMITM (RLF-100TM/aviptadil)
September 28, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Reports Half-Year 2021 Results and Provides Corporate Update
September 24, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Tickers
RLFTF
Relief's Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Data Published in Peer Reviewed Journal, Nutrients, Indicating Additional Potential Benefits of Its Physiomimic(TM) Technology
September 21, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)
September 13, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Launches PKU GOLIKE(R) KRUNCH in Germany and Italy
September 09, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Therapeutics Comments on Certain Statements Made by NRx Pharmaceuticals in its Registration Statement on Form S-1 Filed on September 3, 2021
September 07, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief Reports Regulatory Clearance in Germany to Commence a Multicenter, Double-blind, Randomized Phase 2 Clinical Trial to Evaluate Inhaled Aviptadil for the Treatment of Sarcoidosis
September 02, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
August 31, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced a Positive Safety Report for ZYESAMI(TM) (aviptadil) in NIH Sponsored ACTIV-3 Study in Patients with Life-Threatening COVID-19
August 19, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Tickers
RLFTF
RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
August 09, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Tickers
ACER
Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
July 28, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief and AdVita Close Definitive Agreement for Relief to Acquire All Outstanding Shares of AdVita
July 28, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
RLFTF
Relief Therapeutics Announces CHF 15 Million Private Placement
July 26, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
July 23, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
July 22, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
RLFTF
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
July 20, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
July 13, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
June 29, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
June 21, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
RLFTF
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
June 16, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
June 02, 2021
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Tickers
RLFTF
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.